Medication Review Improves Pain Management and Quality of Life in Chronic Pain
CompletedNot applicableNCT06997861
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this parallel-group, single-blinded, randomized study is to conduct Medication Review (MR) Type III in chronic non-cancer pain patients to optimize drug therapy and measure it's influence on Pain Intensity and Quality of Life in the primary care setting. The study took place in Porto, Portugal with the collaboration of two Primary Care Units (USF Arca D'Água and USF Campanhã - Polo S. Roque da Lameira) under ACeS Porto Oriental, from where patients were recruited. The main question it aims to answer is: * Does the implementation of pharmacist-led medication review benefit patients with chronic pain in the primary care setting? * Researchers will compare with "Usual Care" (UC) patients which receives general advice on how to manage their pain and/or recommendations to take "over the counter" drugs, similar to community pharmacy visits, to see if there is a clinically significant difference in pain intensity and quality of life between the two groups of patients. * Participants will be asked to attend face-to-face interviews once a month for 4 months with an expert in medication review, that evaluates their current medication and suggests an individualized care plan. These plans include measures aimed at physicians (e.g., medication adding; dose reduction) and participants (e.g., non-pharmacological measures; adherence to medication).
Study details
- Official title
- Parallel Randomized Study to Determine Pain Intensity and Quality of Life in Patients With Chronic Non-Cancer Pain Receiving Medication Review With Follow-up VS Usual Care
- Conditions
- Interventions
- Other: Medication Review Type III
- Other: Usual Care
- Sponsor
- Polytechnic Institute of Porto
- Collaborators
- University of Salamanca
- Start date
- 2023-11-03
- Primary completion
- 2024-06-26
- Sex
- All
- Age range
- from 18 Years to 70 Years
- Results posted
- No results posted in this snapshot
- Countries
- Portugal
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Non-cancer chronic pain (\>3 months, any cause) * Follow-up at one of the selected Primary Care Units * Average weekly pain score ≥4 at the screening phase * Ability to attend monthly in-person or video interviews Exclusion Criteria: * Pregnancy * Breastfeeding * Dementia * Other mental illness impairing self-reporting
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT06997861